Life Technologies Responds to Challenge of Detecting Vesivirus 2117 Contamination in Mammalian Cell Culture Manufacturing

New Molecular Test Provides Rapid Sample Preparation and qPCR Method for Specific and Sensitive Detection of This RNA Virus

CARLSBAD, Calif.--()--Life Technologies Corporation (NASDAQ:LIFE) today announced a new molecular test for the detection of Vesivirus 2117, a potential contaminant of mammalian cell culture based biopharmaceutical manufacturing. The Applied Biosystems ViralSEQTM Vesivirus Detection Kit is a highly sensitive and accurate test that enables the quick isolation and detection of Vesivirus 2117 from cell culture samples. It is expected that biopharmaceutical companies will use the kit to detect this potential contamination early in production, safeguarding the manufacturing processes.

Vesivirus is an RNA virus that has re-emerged over the last year as a potential threat in mammalian cell culture production. The ViralSEQTM Vesivirus Detection Kit is a PCR-based test that utilizes PrepSEQTM magnetic bead technology to isolate viral RNA from a wide range of sample types, combined with TaqMan® technology for sensitive and specific detection of the viral RNA. The kit also includes a proprietary positive control molecule that eliminates the possibility of a false positive test result due to an inadvertent contamination of test sample with positive control. The test expands the company’s industry leading portfolio of rapid molecular assays focused on the detection and quantitation of key impurities such as mycoplasma and residual DNA.

“We have focused our efforts on developing a robust method that isolates and detects this virus in a single assay,” said Tony Hunt, Senior Director of Bioproduction at Life Technologies. “This is an important test for the pharmaceutical industry as it enables the detection of this virus in less than five hours. Life Technologies is committed to continued leadership in developing advanced molecular tests, and expanding our portfolio of solutions to better address contamination and impurity issues in biopharmaceutical manufacturing.”

About Life Technologies (

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,600 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

For Research Use Only. Not for use in diagnostic procedures.

Copyright 2010. Life Technologies Corporation. All rights reserved. Applied Biosystems is a registered trademark of Life Technologies or its subsidiaries in the United States and/or certain other countries. TaqMan® is a registered trademark of Roche Molecular Systems, Inc.


Life Technologies
Lauren Lum, 650-638-6916

Release Summary

ViralSEQ is a highly sensitive and accurate test that enables the quick isolation and detection of Vesivirus 2117 from cell culture samples.



Life Technologies
Lauren Lum, 650-638-6916